Phased CpG Methylation Calling in GM24385 with Remora and Clair3

By Chris Wright
Published in Data Releases
January 20, 2022
2 min read

Previously we made available an Oxford Nanopore Open Data release comprising 5-methylcytosine basecalls using the Guppy basecaller tailored to the specific task of identifying 5mC. In this post we present fresh set of basecalls using the new algorithms for the Remora project, and integrated into the research-grade basecaller Bonito.

For more information and help downloading data from our open dataset archive see the Datasets Tutorials page. All the data referred to in this blog can be accessed under:


The most relevant files stored under this top level and referred to below are:

240.6 GiB all.bam
76.9 MiB all.bam.bai
233.6 GiB all.hp.bam
76.9 MiB all.hp.bam.bai
75.2 MiB all_contigs.vcf.gz
1.5 MiB all_contigs.vcf.gz.tbi
891.4 MiB bonito.cpg.bed.gz
1.9 MiB bonito.cpg.bed.gz.tbi
727.9 MiB bonito.hp1.cpg.bed.gz
1.8 MiB bonito.hp1.cpg.bed.gz.tbi
722.6 MiB bonito.hp2.cpg.bed.gz
1.8 MiB bonito.hp2.cpg.bed.gz.tbi

Please also refer to the original post introducing this dataset.

The GM24385 cell line samples were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research.

Bonito-Remora Basecalling

Previous iterations of modified-base basecalling in the Guppy basecaller have required use of a basecalling model specific to the task of identifying modified bases. These models have typically traded the ability to call base modifications for a slight decrease in canonical basecalling accuracy. The advent of the new algorithms of Remora allow highest accuracy basecalling and identification of modified bases in a single basecalling process, reducing the computation requirements to obtain such results.

As with the analysis workflow using Guppy, the Bonito basecaller is capable of outputting BAM files annotated with methylation calls as described in the SAM tags specification found at: Bonito can be provided with a reference genome and instructed to output BAM files with the MM and ML tags described in the specification documents:

bonito basecaller dna_r9.4.1_e8_sup@v3.3 \
<fast5 input directory> \
--modified-bases 5mC \
--reference <minimap2 reference index> \
--recursive \
--alignment-threads 8 \
| samtools view -u | samtools sort -@ 8 > <output.bam>
samtools index <output.bam>

Similarly the resultant BAM file can be summarized to a bedMethyl using the modbam2bed program (available through conda for both Linux and MacOS):

modbam2bed \
-e -m 5mC --cpg -t 10 \
GCA_000001405.15_GRCh38_no_alt_analysis_set.fa \
<bonito bams> ... \
| bgzip -c > bonito.cpg.bed.gz

We therefore have obtained highest accuracy basecalls and modification calls in a useful summarised form with only two computational steps from the primary sequencer measurements.

Figure 1. Heatmaps indicating correlation between CpG site methylation frequencies from bisulfite and nanopore sequencing. Limited to sites with 20 or more spanning reads for both technologies.

Phased Methylation Calls

To further demonstrate the enhanced utility of long-read nanopore sequencing for modified-base identification, we are also providing phased methylation calls. These have been produced de-novo using our wf-human-snp Nextflow workflow to produce phased small variant calls using clair3 and whatshap. The phased variants were used to tag reads as belonging to one of the two haplotypes, and modbam2bed run to produce a bedMethyl file per haplotype.

The variant calling workflow was run using,

nextflow run epi2me-labs/wf-human-snp \
-r v0.1.2 --model r941_prom_sup_g5014 --phase_vcf \
--bam all.bam \
--ref GCA_000001405.15_GRCh38_no_alt_analysis_set.fa \
--out_dir clair3 -w clair3

to produce a VCF file containing phased variants. These phased variants were then used to tag each read as belonging to one of the two haplotypes, whatshap was used for this task with,

whatshap haplotag \
--ignore-read-groups \
--output all.hp.bam \
--reference GCA_000001405.15_GRCh38_no_alt_analysis_set.fa \
all_contigs.vcf.gz all.bam

The above command produced a BAM file with an HP (haplotype) tag for each read. Phased methylation statistics were obtained using modbam2bed with the --haplotype option, once for each haplotype:

for HP in 1 2; do
modbam2bed \
-e -m 5mC --cpg -t 10 --haplotype ${HP} \
GCA_000001405.15_GRCh38_no_alt_analysis_set.fa \
all.hp.bam \
| bgzip -c > bonito.hp${HP}.cpg.bed.gz

As a well-known and characterised example of differential methylation between maternal and paternal haplotypes, Figure 2. depicts sequencing data in the region around the Prader-Willi Syndrome associated gene SNRPN. Using the procedure above sequencing data is tagged as either “haplotype 1” or “haplotype 2”: a striking difference in the rate of 5mC presence is observed.

Phased 5mC Calls
Figure 2. Phased 5mC calls in the vicinity of the Prader-Willi gene SNRPN, depicted in IGV. The presence of 5mC is highlighted in red.; the paternal and maternal copies are differentially methylated.


Here we have shown how the latest software tools from Oxford Nanopore Technologies can be used to obtain simply phased CpG modification calls for the GM24385 human cell-line. The methods used are applicable to any diploid sample. We hope that these new tools will greatly accelerate fields of research where DNA methylation is known to play an important role, and also unlock new insights.


#modifiedbases#gm24385#ont-open-data#human cell-line#R9.4.1phasing


Chris Wright

Chris Wright

Senior Director, Customer Workflows

Related Posts

Nanopore-only T2T assembly of a human genome
May 22, 2024
2 min

Quick Links

TutorialsWorkflowsOpen DataContact

Social Media

© 2020 - 2024 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor, MinION, MinIT, MinKNOW, Plongle, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.